Is IBRX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IBRX. It does not provide personalized investment advice.

IBRX (ImmunityBio, Inc. Common Stock) Stock Analysis - Financials

ImmunityBio, Inc. Common Stock (IBRX) is a publicly traded Healthcare sector company. As of July 6, 2026, IBRX trades at $9.49 with a market cap of $9.89B and a P/E ratio of -11.11. IBRX moved +0.00% today. Year to date, IBRX is +376.77%; over the trailing twelve months it is +257.58%. Its 52-week range spans $1.83 to $12.43. Analyst consensus is strong buy with an average price target of $13.00. Rallies surfaces IBRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are IBRX's key financials?

IBRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. IBRX recently traded at $9.49. Market cap is $9.89B. P/E ratio is -11.11. Revenue is $140.98M.

IBRX Key Metrics

Key financial metrics for IBRX
Metric	Value
Price	$9.49
Market Cap	$9.89B
P/E Ratio	-11.11
EPS	$-0.85
Dividend Yield	0.00%
52-Week High	$12.43
52-Week Low	$1.83
Volume	8.18K
Avg Volume	0
Revenue (TTM)	$140.98M
Net Income	$-854.60M
Gross Margin	99.34%

IBRX Analyst Consensus

3 analysts cover IBRX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $13.00.

Common questions about IBRX

What are IBRX's key financials?: IBRX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. IBRX recently traded at $9.49. Market cap is $9.89B. P/E ratio is -11.11. Revenue is $140.98M.
Is IBRX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IBRX. It does not provide personalized investment advice.